My Account Login | Signup
3.95.139.100Array ( [query_status] => Array ( [query_status_code] => OK [query_status_description] => Query successfully performed. ) [ip_address] => 3.95.139.100 [geolocation_data] => Array ( [continent_code] => NA [continent_name] => North America [country_code_iso3166alpha2] => US [country_code_iso3166alpha3] => USA [country_code_iso3166numeric] => 840 [country_code_fips10-4] => US [country_name] => United States [region_code] => VA [region_name] => Virginia ) )
Home
Editorial Board
Submit article
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Free Articles
Purchase Single Articles
Archive
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
Subscribe
FAQ
Contact Us
Journal of Pharmaceutical and Medicinal Chemistry

Volume  5, Issue 1, January-June 2019, Pages 47-54

 

Review Article

A Review on Oral Hypoglycemic Drugs
Dulal Ch. Roy1, Arjun Kafle2
1Professor cum Principle Investigator 2Junior Research Fellow, Department of Pharmacology and Toxicology, College of Veterinary Science, Assam Agricultural University, Khanapara, Guwahati, Assam 781022, India.
Choose an option to locate / access this Article:
Check if you have access through your login credentials.             |
|

DOI: http://dx.doi.org/10.21088/jpmc.2395.6615.5119.6

Abstract

Globally, an estimated 422 million adults are living with diabetes mellitus, according to the latest 2016 data from the World Health Organization. Diabetes is a group of disorder characterized by high blood glucose level. Constant high level of blood glucose may lead to many life-threatening complications viz, cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes. The treatment strategy is mainly targeted to lower blood glucose level by one or other means. This can be achieved by either slowing down the rate by which glucose enters into the bloodstream (Biguanides: Metformin; α-Glucosidase inhibitor: Acarbose etc) or by stimulating body’s ability to utilize the glucose present in the blood by the cells (Sulfonylureas: Chlorpropamide; Thiazolidinediones: Pioglitazone; GLP-1 analogue; DPP 4 inhibitors; Exenatide). This review focuses on conventional antidiabetics currently used and drawbacks associated with it and newer oral hypoglycemic agents with their advantages over the conventional ones.


Corresponding Author : Dulal Ch. Roy